1. Repeated CyberKnife stereotactic body radiation therapy in hepatocellular carcinoma
- Author
-
Dan Zhang, Quan Wang, Aimin Zhang, Xuezhang Duan, Dong Li, Jia Wang, Xiaoyun Chang, Wengang Li, Jing Sun, and Can Ouyang
- Subjects
Adult ,Male ,lcsh:Medical physics. Medical radiology. Nuclear medicine ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Stereotactic body radiation therapy ,Hepatocellular carcinoma ,medicine.medical_treatment ,lcsh:R895-920 ,Urology ,Radiosurgery ,lcsh:RC254-282 ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Cyberknife ,medicine ,Overall survival ,Humans ,Radiology, Nuclear Medicine and imaging ,General hospital ,Aged ,business.industry ,Research ,Liver Neoplasms ,Middle Aged ,medicine.disease ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Radiation therapy ,Second-course radiotherapy ,Oncology ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,business - Abstract
Background To explore the survival and side effects of repeated CyberKnife stereotactic body radiation therapy (CK-SBRT) on hepatocellular carcinoma patients. Methods 24 HCC patients were collected at The Fifth Medical Center of PLA General Hospital from November 2011 to July 2016. They received second-course CK-SBRT with a prescribed dose of 50(48–55) Gy/5-8fx, and a single dose of 10 (7–11) Gy/fx. Cumulative overall survival rates (OS), progression-free survival rates (PFS) and local control rates (LC) were calculated by Kaplan-Meier method. Results All patients finished their radiotherapy plans. The 1-,2- and 3-year cumulative OS rate were 95.8,81.1 and 60.8%. The 1-,2- and 3-year LC rate were 95.5,90.7 and 90.7%, respectively. The 1-, 2- and 3-year PFS were 74.8, 49.2 and 39.4%, respectively. 16 patients complained of fatigue during second-course therapy, 2 patients showed Grade 2 gastrointestinal reaction, 1 patient was diagnosed radiation-induced liver disease and none died. PFS was significantly higher in the interval time p = 0.030). Conclusions It is preliminarily believed that re-CK-SBRT is an effective and safe treatment for HCC patients, but the treatment criteria should be strictly controlled.
- Published
- 2020